Alpha Cognition Inc. (ACOG)
- Previous Close
5.49 - Open
5.52 - Bid 5.23 x 100
- Ask 5.61 x 100
- Day's Range
5.52 - 5.63 - 52 Week Range
3.75 - 7.00 - Volume
678 - Avg. Volume
62,072 - Market Cap (intraday)
90.195M - Beta (5Y Monthly) 2.51
- PE Ratio (TTM)
-- - EPS (TTM)
-2.02 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
27.40
Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is based in Vancouver, Canada.
www.alphacognition.comRecent News: ACOG
View More
Performance Overview: ACOG
Trailing total returns as of 5/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ACOG
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ACOG
View MoreValuation Measures
Market Cap
86.75M
Enterprise Value
39.11M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.09
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-28.00%
Return on Equity (ttm)
-79.64%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-14.64M
Diluted EPS (ttm)
-2.02
Balance Sheet and Cash Flow
Total Cash (mrq)
48.55M
Total Debt/Equity (mrq)
2.20%
Levered Free Cash Flow (ttm)
-3.9M